Nursing Elites

1. A healthcare professional is reviewing a new prescription for Ondansetron 4 mg PO PRN for nausea and vomiting for a client who has Hyperemesis Gravidarum. The healthcare professional should clarify which of the following parts of the prescription with the provider?

• A. Name
• B. Dosage
• C. Route
• D. Frequency

Correct answer: D

Rationale: The prescription lacks the frequency of medication administration, which is crucial for ensuring appropriate use. In this case, the frequency of when the medication can be taken needs to be clarified with the provider to provide safe and effective care for the client with Hyperemesis Gravidarum.

2. A healthcare professional is preparing to administer eye drops to a client. Which of the following actions should the healthcare professional take? (Select all that apply.)

• A. Have the client lie on their side.
• B. Ask the client to look up at the ceiling.
• C. Tell the client to blink when the drops enter their eye.
• D. Drop the medication into the center of the client's conjunctival sac.

Correct answer: B

Rationale: When administering eye drops, it is essential to ask the client to look up at the ceiling. This position helps prevent the drops from falling onto the cornea, ensuring that the medication is properly absorbed without causing discomfort or irritation.

3. A healthcare provider is planning to administer IV Alteplase to a client who is demonstrating manifestations of a massive Pulmonary Embolism. Which of the following interventions should the healthcare provider plan to take?

• A. Administer IM Enoxaparin along with the Alteplase dose.
• B. Hold direct pressure on puncture sites for up to 30 minutes.
• C. Administer Aminocaproic acid IV prior to alteplase infusion.
• D. Prepare to administer Alteplase within 8 hours of manifestation onset.

Correct answer: B

Rationale: When administering IV Alteplase for a massive Pulmonary Embolism, the healthcare provider should plan to hold direct pressure on puncture sites for 10 to 30 minutes or until oozing of blood stops. This is crucial to prevent bleeding complications at the puncture sites. Choice A is incorrect because Enoxaparin is not usually administered along with Alteplase for a Pulmonary Embolism. Choice C is incorrect because Aminocaproic acid is not typically given prior to alteplase infusion in this situation. Choice D is incorrect because Alteplase should be administered within 2 hours of onset of manifestations for Pulmonary Embolism, not within 8 hours.

4. A healthcare professional is providing discharge instructions to a client who has a new prescription for Enoxaparin. Which of the following instructions should the healthcare professional include?

• A. Inject the medication into the muscle.
• B. Massage the injection site after administration.
• C. Rotate injection sites between the arms and thighs.
• D. Administer the medication in the abdomen.

Correct answer: D

Rationale: The correct instruction is to administer Enoxaparin in the abdomen as a subcutaneous injection. This method helps prevent bleeding complications associated with the medication. Massaging the injection site after administration should be avoided to reduce the risk of local irritation or bleeding. While rotating injection sites between the arms and thighs is a good practice for some medications, it is not recommended for Enoxaparin. Consistent administration in the abdomen ensures optimal absorption and helps avoid complications.

5. A client is receiving epoetin alfa to treat anemia. Which of the following findings should the nurse monitor?

• A. Leukocytosis
• B. Hypertension
• C. Hyperkalemia
• D. Fever

Correct answer: B

Rationale: The nurse should monitor the client for hypertension when receiving epoetin alfa. Epoetin alfa stimulates red blood cell production, which can lead to increased blood pressure. Monitoring blood pressure is crucial to detect and manage hypertension promptly. Leukocytosis refers to an increased white blood cell count and is not directly related to epoetin alfa treatment. Hyperkalemia is an elevated potassium level, which is not a common adverse effect of epoetin alfa. Fever is not a typical finding associated with epoetin alfa therapy.

Similar Questions